The Effects of a Fixed Combination of Berberis aristata and Silybum marianum on Dyslipidaemia - A Meta-analysis and Systematic Review.

摘要: A fixed combination of Berberis aristata and Silybum marianum (Berberol) has been used by patients with dyslipidaemia. The aim the present meta-analysis was to systematically evaluate efficacy safety a B. S. on serum lipid levels compared placebo in based randomised, controlled trials. reported according Preferred Reporting Items for Systematic Reviews Meta-Analyses statement, using PICO (patients, intervention, comparison, outcome) format, it registered International Prospective Register Reviews. Cochrane Central Controlled Trials, PubMed, Embase, Web Science databases were searched relevant studies. Placebo-controlled clinical studies involving adult condition dyslipidaemia receiving included. Four randomised trials, including total 491 patients, pooled statistical analysis. According meta-analysis, Berberol significantly lowered low-density lipoprotein level, cholesterol, fasting plasma glucose levels, Homeostatic Model Assessment index placebo; however, its effects high-density triglyceride body mass not statistically significant end 3-month treatment period. appeared be safe, did increase alanine transaminase, aspartate creatine kinase enzymes. is an effective presumably safe complementary therapy dyslipidaemia; evidence supporting use very limited. optimum dose duration are unclear. comprehensive evaluation required further high-quality larger patient populations.